Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Journal of Chemical Information and Modeling|January 11, 2008
Small molecule conformational preferences derived from crystal structure data. A medicinal chemistry focused analysisKen A Brameld, Bernd Kuhn, Deborah C Reuter, et al.Angewandte Chemie (International Ed. in English)|June 22, 2019
The Proteome-Wide Potential for Reversible Covalency at CysteineKristine Senkane, Ekaterina V Vinogradova, Radu M Suciu, et al.Journal of Immunology (Baltimore, Md. : 1950)|March 6, 2021
Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated DiseaseClaire L Langrish, J Michael Bradshaw, Michelle R Francesco, et al.Bioorganic & Medicinal Chemistry Letters|December 15, 2010
Quinolones as HCV NS5B polymerase inhibitorsDange V Kumar, Roopa Rai, Ken A Brameld, et al.Molecular Cancer Therapeutics|October 6, 2017
The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug ClearanceEleni Venetsanakos, Ken A Brameld, Vernon T Phan, et al.Bioorganic & Medicinal Chemistry Letters|November 29, 2011
3-heterocyclyl quinolone inhibitors of the HCV NS5B polymeraseDange V Kumar, Roopa Rai, Ken A Brameld, et al.Journal of Medicinal Chemistry|July 1, 2017
Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid TumorsKen A Brameld, Timothy D Owens, Erik Verner, et al.The Journal of Biological Chemistry|January 17, 2015
Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694Yiming Zhong, Shuai Dong, Ethan Strattan, et al.Journal of Medicinal Chemistry|September 28, 2013
Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5BRyan C Schoenfeld, David L Bourdet, Ken A Brameld, et al.Journal of Medicinal Chemistry|March 21, 2013
De novo fragment design: a medicinal chemistry approach to fragment-based lead generationFrancisco X Talamas, Gloria Ao-Ieong, Ken A Brameld, et al.Pageof 2